EUVIMEDEUVIMED entdecken
Crossref

Formulation of bortezomib human serum albumin nanoparticles, in vitro and in vivo evaluation

Areej W. Alhagiesa, Mowafaq M. Ghareeb

ACTA Pharmaceutica Sciencia · 2026 · 64 (2) · 259

DOI: 10.23893/1307-2080.aps64015 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACTA Pharmaceutica Sciencia, 2026. Verfasst von Areej W. Alhagiesa und 1 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Alhagiesa, A. W., & Ghareeb, M. M. (2026). Formulation of bortezomib human serum albumin nanoparticles, in vitro and in vivo evaluation. ACTA Pharmaceutica Sciencia, 64(2), 259. https://doi.org/10.23893/1307-2080.aps64015

Vancouver

Alhagiesa AW, Ghareeb MM. Formulation of bortezomib human serum albumin nanoparticles, in vitro and in vivo evaluation. ACTA Pharmaceutica Sciencia. 2026;64(2):259. doi:10.23893/1307-2080.aps64015

BibTeX
@article{Alhagiesa2026,
  author = {Alhagiesa, Areej W. and Ghareeb, Mowafaq M.},
  title = {Formulation of bortezomib human serum albumin nanoparticles, in vitro and in vivo evaluation},
  journal = {ACTA Pharmaceutica Sciencia},
  year = {2026},
  volume = {64},
  number = {2},
  pages = {259},
  doi = {10.23893/1307-2080.aps64015}
}
Kostenlos starten →